Please Wait
Applying Filters...
menu
    • menu
    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-08-25

    Virtual Booth

    An Enquiry

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-08-25

    Virtual Booth

    An Enquiry

    Menu

    Blarcamesine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Anavex Reports Journal on Autophagy Mechanism with Blarcamesine
    Anavex Reports Journal on Autophagy Mechanism with Blarcamesine

    26 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/26/3139157/29248/en/Anavex-Life-Sciences-Reports-New-Publication-in-Medical-Journal-Highlighting-the-Established-Precise-Autophagy-Mechanism-with-Blarcamesine.html

    GLOBENEWSWIRE
    26 Aug 2025
    Share Share
    Anavex's Blarcamesine Prevents Alzheimer’s in Animal Study
    Anavex's Blarcamesine Prevents Alzheimer’s in Animal Study

    20 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/20/3136316/29248/en/Anavex-Life-Sciences-Announces-New-Publication-in-Medical-Journal-Blarcamesine-Prevented-Cognitive-Impairment-in-Animal-Model-of-Alzheimer-s-Disease.html

    GLOBENEWSWIRE
    20 Aug 2025
    Share Share
    Anavex Reports 4-Year Data From Blarcamesine Alzheimer Trial
    Anavex Reports 4-Year Data From Blarcamesine Alzheimer Trial

    31 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/31/3124886/29248/en/Anavex-Life-Sciences-Announces-Positive-Precision-Medicine-Results-from-up-to-4-Years-of-Oral-Blarcamesine-Treatment-in-Phase-IIb-III-Open-Label-Extension-Trial-in-Early-Alzheimer-.html

    GLOBENEWSWIRE
    31 Jul 2025
    Share Share
    Anavex Life Sciences Reports Positive 4-Year Blarcamesine Results
    Anavex Life Sciences Reports Positive 4-Year Blarcamesine Results

    05 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/05/3056284/29248/en/Anavex-Life-Sciences-Announces-Positive-up-to-4-Years-Oral-Blarcamesine-Results-from-Phase-IIb-III-Open-Label-Extension-Trial-in-Early-Alzheimer-s-Disease.html

    GLOBENEWSWIRE
    05 Apr 2025
    Share Share
    Anavex Expands IP With Blarcamesin U.S. Patent Issuance
    Anavex Expands IP With Blarcamesin U.S. Patent Issuance

    27 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/27/3015498/29248/en/Anavex-Life-Sciences-Announces-Issuance-of-Blarcamesine-ANAVEX-2-73-Composition-of-Matter-U-S-Patent-Expanding-its-Intellectual-Property-Portfolio.html

    GLOBENEWSWIRE
    27 Jan 2025
    Share Share
    Anavex's Alzheimer Treatment Result Published In Journal
    Anavex's Alzheimer Treatment Result Published In Journal

    15 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/15/3009934/29248/en/Anavex-Life-Sciences-Announces-Peer-Reviewed-Publication-of-Oral-Blarcamesine-Phase-IIb-III-Data-in-The-Journal-of-Prevention-of-Alzheimer-s-Disease.html

    GLOBENEWSWIRE
    15 Jan 2025
    Share Share